6JJ3

BRD4 in complex with 138A

Summary for 6JJ3

• Entry DOI: 10.2210/pdb6jj3/pdb
• Descriptor: Bromodomain-containing protein 4, 2-methoxy-N-[2-methyl-6-(4-methylpiperazin-1-yl)-3-oxidanylidene-2,7-diazatricyclo[6.3.1.0^{4,12}]dodeca-1(12),4,6,8,10-pentaen-9-yl]benzenesulfonamide (3 entities in total)
• Functional Keywords: brd4, inhibitor, signaling protein-inhibitor complex, signaling protein/inhibitor
• Biological source: Homo sapiens (Human)
• Total number of polymer chains: 1
• Total formula weight: 15350.73

Authors

Xu, J.,Chen, Y.,Jiang, F.,Zhu, J. (deposition date: 2019-02-25, release date: 2020-01-22, Last modification date: 2024-03-27)

Primary citation

Jiang, F.,Hu, Q.,Zhang, Z.,Li, H.,Li, H.,Zhang, D.,Li, H.,Ma, Y.,Xu, J.,Chen, H.,Cui, Y.,Zhi, Y.,Zhang, Y.,Xu, J.,Zhu, J.,Lu, T.,Chen, Y.
Discovery of Benzo[cd]indol-2(1H)-ones and Pyrrolo[4,3,2-de]quinolin-2(1H)-ones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain with Potential High Efficiency against Acute Gouty Arthritis.
J.Med.Chem., 62:11080-11107, 2019

PubMed Abstract: The bromodomain and extra-terminal domain (BET) family of proteins are readers which specifically recognize histone-acetylated lysine residues. Each BET bromodomain protein contains two highly homologous domains: the first bromodomain (BD1) and the second bromodomain (BD2). Pan-BET bromodomain inhibition is a potential therapy for various cancers and immune-inflammatory diseases, but only few reported inhibitors show selectivity within the BET family. Herein, we identified a series of benzo[]indol-2(1)-ones and pyrrolo[4,3,2-]quinolin-2(1)-ones with good selectivity for BET BD1. Through structure-based optimization, highly active and selective compounds are ultimately obtained. The representative compounds are the first reported inhibitors with selectivity more than 100-fold for BRD4(1) over BRD4(2). Among them, we further show that (LT052) mediates BRD4/NF-κB/NLRP3 signaling inflammatory pathways with comparable protein expression and significantly improves symptoms of gout arthritis in a rat model. Therefore, selective pharmacological modulation of individual bromodomains could represent a strategy for the treatment of acute gouty arthritis.

PubMed: 31789032
DOI: 10.1021/acs.jmedchem.9b01010

Experimental method

X-RAY DIFFRACTION (1.718 Å)